Nektar Therapeutics Stock Analysis (NASDAQ:NKTR)

Add to My Stocks
$24.2 $0.27 (1.13%) NKTR stock closing price Mar 29, 2017 (Closing)
Watch Robo Advisor Video of NKTR Stock Analysis
Nektar Therapeutics
Updated on : Mar 29, 2017
previous close
NKTR 24.2 (0%)
S&P 500 2361.1 (0%)
Closing Price On: Mar 29, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
18.3%
Operating Profit
Operating Margin:
-68.2%
Sector Average:
-6.4%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Debt/Equity Ratio
Debt:
248.6M
Debt/Equity Ratio:
 2.82
Compared to the industry
Cash Flow
Operating cash flow:
-$52.4M
Net Income:
-$42.2M
PROS      CONS
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
FCF Margin
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
NKTR PS :
21.8
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-118.8%
Free Cash Flow Margin:
-147%
Double Tap To Exit Full Screen
0:00
/

Nektar Therapeutics Analysis Video

79 5 2

View Nektar Therapeutics stock analysis video. This is our NKTR analyst opinion covering the buy and sell arguments for NKTR stock.

Nektar Therapeutics Stock Rating (2.3/5)

Our Nektar Therapeutics stock opinion is based on fundamentals of the company. This Nektar Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy NKTR stock?

  • Long term revenue growth has been strong with a 5 year compounded annual growth of 18.3%.

Should you sell NKTR stock?

  • Over the last twelve months, Nektar Therapeutics posted an average operating loss margin of -68.2%.
  • Nektar Therapeutics registered an average TTM Net loss of -92.8%.
  • Nektar Therapeutics has a debt/equity ratio of  2.82, which is worse than the average in the Medical sector.
  • PE ratio is meaningless for NKTR stock as the company has losses.
  • NKTR stock is trading at a PS multiple of 21.8, which is a negative when compared to the Medical-Drugs industry average multiple of 4.7.
  • Nektar Therapeutics's negative ROIC of -118.8% indicates operational inefficiency.
  • The company has a negative free cash flow margin of -147%.

Comments on this video and Nektar Therapeutics stock